Evommune Bets $30M on Oral VAV1 Degrader With No Validated RA Precedent

Evommune Licenses Molecular Glue Degrader for Autoimmune Diseases

Evommune has licensed an oral molecular glue degrader, EVO570, from Hinova Pharmaceuticals in a deal potentially worth up to $1.1 billion in milestones, plus a $30 million upfront payment. This agreement grants Evommune worldwide rights, excluding Greater China, to the VAV1-directed candidate. EVO570 is slated for a mid-stage trial in rheumatoid arthritis in 2027, with a Phase 1 study expected to launch imminently after clinical trial requests were accepted in the U.S. and submitted in China. This strategic move aims to address a pipeline gap for Evommune following recent clinical failures of its asset EVO756.

• Evommune's strategic licensing agreement with Hinova Pharmaceuticals includes a $30 million upfront payment, consisting of $20 million cash and $10 million in pre-funded warrants. The deal also features potential milestone payments up to $1.1 billion and royalties on net sales outside of China, securing global rights for the VAV1-directed molecular glue degrader, EVO570, excluding the Greater China area.
• EVO570, formerly known as HC118 and HP570, targets VAV1, a signaling protein predominantly found in immune cells that drives T and B cell activation in chronic inflammatory diseases. This molecular glue degrader is designed to eliminate VAV1, aiming for improved safety and tolerability compared to current JAK inhibitor treatments. Preclinical studies showed EVO570 to be 20 times more potent than Novartis’ oral molecular glue degrader MRT-6160.
• The acquisition of EVO570 is a critical move for Evommune, providing a near-term clinical catalyst and addressing a 'catalyst vacuum' after its oral asset EVO756 failed in mid-stage studies for chronic spontaneous urticaria and atopic dermatitis. With over 1.2 million U.S. patients suffering from rheumatoid arthritis, this deal positions Evommune to tap into a significant commercial opportunity, potentially offering a first-in-class program in a market with unmet needs due to safety concerns with existing oral therapies.

Unlocking Rheumatoid Arthritis: EVO570's Novel VAV1 Degradation

Receptor-interacting protein kinase 1 (RIPK1) is being investigated as a mediator of inflammation through cell death and proinflammatory cytokine production. GSK2982772 60 mg orally 2 or 3 times daily for 84 days was evaluated in a multicenter, randomized, double-blind (sponsor-unblinded), placebo-controlled, experimental medicine study in moderate to severe rheumatoid arthritis (RA) in patients who had received ≥12 weeks' stable-dose conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy (ClinicalTrials.gov Identifier: NCT02858492). Disease Activity Score in 28 Joints-C-reactive protein (DAS28-CRP) scores, ACR20/50/70 response, and rates of low disease activity and remission were similar between placebo and GSK2982772 arms, with results suggesting that inhibition of RIPK1 activity at the GSK2982772 exposure levels evaluated do not translate into meaningful clinical improvement of RA. Ocadusertib, a potent and selective allosteric inhibitor of RIPK1, inhibited RIPK1 enzymatic activity with high potency (half-maximal inhibitory concentration [IC] = 12-38 nM) with no significant inhibition of more than 100 other kinases, prevented RIPK1-dependent hypothermia in response to tumor necrosis factor (TNF) challenge and reduced disease severity in a model of chronic proliferative dermatitis, showed linear pharmacokinetics and dose-proportional exposure with time to maximum concentration of 1-4 h and half-life of 13-15 h, steady state at 4-6 days after multiple once-daily dose administrations, and greater than 90% RIPK1 target engagement was achieved at Day 14. Agents in active development for RA treatment include those targeted to CD40 and CD40 ligand, programmed death protein 1 (PD-1), and granulocyte-macrophage colony-stimulating factor (GM-CSF), with interleukin 1 receptor associated kinases 1 and 4 (IRAK1, IRAK4), tyrosine kinase 2 (Tyk2), bradykinin receptor 1 (B1R), OX40 and OX40 ligand evaluated in preclinical or translational studies, while patients with active RA expressed higher basal intracellular levels of NLRP3, ASC, active caspase-1 and pro-IL-1β with increased NLRP3-mediated IL-1β secretion upon TLR3 and TLR4 stimulation.

Cytokine blockade strategies center on granulocyte-macrophage colony stimulating factor (GM-CSF), Th17 biology, and dual cytokine neutralization. GM-CSF was one of the first cytokines detected in human synovial fluid from inflamed joints, with therapies targeting GM-CSF or its receptor tested in preclinical studies and early phase clinical trials evaluating GM-CSF antagonism in inflammatory disorders. Interleukin (IL)-12, IL-23 and IL-17 in addition to the TNF superfamily and the adipocytokines are described as potential novel cytokine targets, with IL-17A inhibitors including the anti-IL-17A monoclonal antibodies secukinumab and ixekizumab and the anti-IL-17RA monoclonal antibody brodalumab. Dual neutralisation of interleukin (IL)-17A and IL-17F with bimekizumab, a monoclonal IgG1 antibody, in addition to certolizumab pegol (CZP) was evaluated in a phase 2a, double-blind, proof-of-concept study (NCT02430909) in which patients with moderate-to-severe RA received open-label CZP 400 mg at Weeks 0, 2 and 4, and 200 mg at Week 6, with inadequate response at Week 8 defined as Disease Activity Score 28-joint count C-reactive protein (DAS28(CRP))>3.2 and randomization to CZP (200 mg every 2 weeks (Q2W)) plus bimekizumab (240 mg loading dose then 120 mg Q2W) or CZP plus placebo showing greater reduction in DAS28(CRP) between Weeks 8 and 20 with 99.4% posterior probability. CD4+ T-cell gene expression studies identified overexpression of 34 genes in early RA compared with osteoarthritis controls, 19 related to interferon (IFN)-γ and eight related to interleukin (IL)-17A, with plasma IFN-γ correlation to DAS28-ESR (Rho=0.553, p=0.0025). New therapeutic antibodies modulating anti-inflammatory cytokines IL-2 and IL-10 and pro-inflammatory mediators GM-CSF, fractalkine, and IL-6 are in various stages of clinical development, while agents targeting IL-15, the IL-20 family, IL-21, chemokine CXCL10, B-cell activating factor (BAFF), and regulatory T (Treg) cells were discussed as unsuccessful therapies.

Stromal, synovial and bone-remodeling pathways define a distinct axis of emerging targets mediated by fibroblast-like synoviocytes (FLSs). Cadherin-11 expression on FLS governs processes resulting in destructive synovitis, with interaction of mesenchymal stem cells with FLS via cadherin-11 promoting angiogenesis by enhanced secretion of placental growth factor (PlGF), and mechanical forces triggering invasive behavior through N-cadherin/ADAM15-dependent modulation of LncRNA H19 leading to upregulation of cadherin-11 (CDH11). NOTCH3 signalling drives differentiation of perivascular and sublining fibroblasts expressing CD90, with NOTCH3 and Notch target genes markedly upregulated in synovial fibroblasts in active RA and genetic deletion of Notch3 or blockade of NOTCH3 signalling attenuating inflammation and preventing joint damage in inflammatory arthritis. Synovial tissue receptor activator of nuclear factor-κβ ligand (RANKL) expression correlated with baseline CRP levels (r = 0.61, P < 0.01) and with erosive progression at 1 year (r = 0.71, P < 0.01), with the RANKL:OPG ratio remaining unaltered even at the highest levels of clinical response to anakinra 100 mg/day as monotherapy or in combination with pegsunercept 800 μg/kg twice weekly. SBT777101, a CAR-Treg therapy targeting citrullinated proteins associated with rheumatoid arthritis and hidradenitis suppurativa, maintained phenotypic stability under repeated stimulation and pro-inflammatory conditions, produced minimal pro-inflammatory cytokines, and showed no evidence of CAR-mediated cytotoxicity or activation in normal human tissues.

Navigating Rheumatoid Arthritis: Addressing Current Treatment Limitations

Despite advances with biologic and targeted synthetic DMARDs, management of rheumatoid arthritis remains constrained by refractory disease, safety trade-offs, and loss of control during de-escalation. A substantial percentage of patients fail primary or secondary responses to bDMARD therapy, and treatment of difficult-to-treat rheumatoid arthritis refractory to multiple b/tsDMARDs remains one of the greatest unmet needs. These limitations shape decisions around continuation, tapering, and switching across drug classes.

• Refractory and difficult-to-treat disease: Of 2128 cases in the FIRST Registry, 353 were categorised as D2T RA and 106 as very D2T RA, defined as failure to ≥2 and ≥3 b/tsDMARDs respectively. Because RA is heterogeneous with overlapping but distinct pathological roles for TNF-α and IL-6, further studies are required to determine best use of TNF inhibitors and tocilizumab in individual patients.

• High relapse risk after discontinuation and flare risk with tapering: Feasibility of DMARD discontinuation after remission or low disease activity has shown high risk of relapse, ranging from 56%-87% at one year. Disease activity-guided tapering enabled 37% (35/95) versus 2% (1/47) to achieve ≥50% biologic reduction at 18 months while disease activity remained equivalent [mean difference 0.05, 95% CI -0.12-0.29], but flare risk was higher [tapering 41% (39/95) vs control 21% (10/47), risk difference 20%, 95% CI 4%-35%].

• Serious infections, malignancy and tuberculosis: In large RCTs of TNF-α antagonists, 35%-67% vs 9%-33% achieved ACR20, but 1 meta-analysis (>5000 patients) reported a 2-fold increase (95% CI, 1.3-3.1) in risk of serious infections and a 3.3-fold increase (95% CI, 1.2-9.1) in risk of malignancy. Reactivation of latent tuberculosis infection is a serious issue after anti-TNFs therapy, which reinforces TB granuloma formation and maintenance; screening for latent TB before initiation is recommended and treatment with TNF inhibitors is to be withheld until infection has resolved.

• Drug-induced lung disease and cardiovascular and other JAK inhibitor signals: Conventional DMARDs such as methotrexate or leflunomide and biological agents such as TNF-blocking agents or rituximab may trigger or aggravate ILD, with prevalence of interstitial pneumonia among RA patients treated with anti-TNF agents ranging from 0.5 to 3%. JAK inhibitors show rapid onset and efficacy in monotherapy with oral administration, but safety compared with biologic therapy includes higher incidence of herpes zoster, and increased incidence of major cardiovascular disease, thromboembolic complications, and cancer in at-risk patients is discussed.

• Immunogenicity and loss of drug survival: Infliximab and adalimumab can induce anti-infliximab and anti-adalimumab antibodies that decrease possibility of achieving minimal disease activity or remission, decrease drug survival, increase need for higher dosage and favor adverse events. ADA positivity was associated with low drug concentrations, poor clinical outcome, and reduced drug survival for TNF-inhibitor monoclonal antibodies, while concomitant methotrexate is associated with increased drug concentrations and reduced immunogenicity.

• Residual pain, fatigue and treatment burden: Forty-eight percent of Rem/RA still declared unacceptable pain (VAS-Pain >20) compared to 80% of H-Mo/RA patients (p<0.0001), regardless of Krenn synovitis score, while fatigue prevalence declined from 69% at baseline to 38% at 24 months during treat-to-target therapy. Biologics are costly, potentially inconvenient, and carry risks of side effects, with lacking consensus across guidelines on how and when to consider therapy de-escalation.